Conference Coverage
Conference Coverage
It’s okay to say ‘no’: Setting boundaries in oncology
Having set boundaries “provides more emotional and cognitive flexibility, and less uncertainty, in the relationships that we have with our...
Conference Coverage
Less therapy may suit older patients with breast cancer
“Do we absolutely have to do a mastectomy for a patient who has a second episode of cancer in the same breast? The answer is no.”
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Conference Coverage
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
It’s challenging for some oncologists to keep up with the nuances of a rapidly changing field, said the author of new research.
Conference Coverage
‘Best’ for most APL patients: Chemo-free regimen
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
Conference Coverage
CAR-T hikes overall survival in relapsed/refractory LBCL
Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
Conference Coverage
Metronomic chemotherapy performs well in second-line head and neck cancer
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.